According to the Center for Disease Control and Prevention (CDC), of all of the bacterial resistance problems, Gram-negative pathogens are particularly worrisome. This is due to their constantly increasing resistance against nearly all available lines of treatment. In fact, Gram-negative bacteria are considered to be amongst the most serious threats to public health, with healthcare-associated infections representing the biggest challenge. The most common pathogens responsible for such threats include Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter.
AIC499 is an innovative beta-lactam antibiotic which addresses the urgent unmet medical need arising from hospital-acquired infections with Gram-negative bacteria. In combination with a beta-lactamase inhibitor (BLI), AIC499 shows very potent antibacterial activity against Gram-negative pathogens including multi-drug resistant strains of P. aeruginosa and Acinetobacter. Due to its unique profile and extensive coverage, AIC499 has the potencial to become the best treatment option for present and future resistant Gram-negative infections.
AIC499 is currently in Phase 1 clinical development supported by the European Medicines Initiative (IMI). It is planned to continue development within IMI up to end of clinical Phase2.
If you have further questions regarding partnering of our projects please contact: